HIV Country Intelligence - HIV Country Profiles
Vol. 2: Clinicians' Guide
Clinicians’ Guide is designed to assist busy medical practitioners in the field with patient management by providing current, essential, practical guidance and background, packaged into a single resource
Bulletin of the World Health Organization, 2001, 79 (4)
The target audience for this guideline is primarily for health care providers nurses, doctors, social workers and other people involved in HIV response in Rwanda so that they are capable of offering quality care services to patients over a long time. The new National Guidelines for Prevention and Ma...nagement of HIV and STIs are articulated in accordance to treat all HIV+ patients regardless of CD4 count and a new service delivery model to support its implementation.
more
N Engl J Med 2019;380:2429-39.DOI: 10.1056/NEJMoa1901113
Medical oxygen is an essential medicine in the treatment of COVID-19. How is it used? Why is there a shortage in some countries and what are WHO, partners and Governments doing about it? WHO’s Dr Janet Diaz explains in Science in 5.
Em vista do aumento repentino do número de hospitalizações causadas pela pandemia de COVID-19 na América Latina e no Caribe, bem como da escassez de recursos humanos e materiais, como equipes médicas e gases medicinais, é necessário reformular os modelos de atenção na Região de modo a otim...izar o que já está disponível e garantir que mais pacientes recebam oxigênio na quantidade necessária e com a qualidade adequada O oxigênio consta na lista de medicamentos essenciais da Organização Mundial da Saúde sendo usado na atenção a pacientes em todos os níveis das redes integradas de serviços de saúde. Considerando que já está comprovada a eficácia do uso de oxigênio no tratamento de pacientes com afecções respiratórias causadas pela COVID-19, há uma grande oportunidade de melhorar a efetividade caso se promova seu uso racional, sustentável e seguro.
more
El oxígeno está incluido dentro de la lista de medicamentos esenciales de la OMS y es utilizado para atender pacientes en todos los niveles de las redes integradas de servicios de salud. Dado que la eficacia del uso de oxígeno ya está probada en el tratamiento de pacientes con afecciones respira...torias provocadas por la COVID-19, existe una gran oportunidad para mejorar la efectividad promoviendo su uso de una manera racional, sostenible y segura.
more
Avec l’augmentation soudaine du nombre d’hospitalisations causées par la pandémie de COVID-19 en Amérique latine et dans les Caraïbes, et étant donné la rareté des ressources humaines et matérielles telles que les équipements médicaux et les gaz médicaux, il est devenu nécessaire de ...repenser les modèles de soins dans la Région dans le but d’optimiser l’utilisation de ce qui est disponible et de s’assurer qu’un plus grand nombre de patients recevront l’oxygène dont ils ont besoin en quantité et en qualité. L’oxygène est inclus dans la liste des médicaments essentiels de l’Organisation mondiale de la Santé et sert à soigner les patients à tous les niveaux des réseaux de services de santé intégrés. L’efficacité de l’utilisation de l’oxygène est démontrée dans le traitement de patients atteints de maladies respiratoires causées par la COVID-19, et cette efficacité pourra être grandement améliorée si on encourage le recours rationnel, durable et sûr à cette pratique.
more
a depresión es una afección importante. Es la principal causa de discapacidad en todo el mundo y puede ser causa de suicidio. En este manual se presenta una versión modificada de la terapia interpersonal para la depresión, a fin de que se pueda utilizar en ocho sesiones grupales bajo un formato ...simplificado para facilitadores. Contiene ejercicios prácticos grupales e individuales para ayudar a las personas a comprender los problemas que contribuyen a su depresión y encontrar maneras de manejarlos más eficazmente.
more
For patients on HFNO with persistent hypoxaemia or respiratory distress:
• Check the equipment: inspect the exterior of the machine, the tubing (circuit), the prong for any sign of mechanical damage, confirm it fits and the filters are in place. Ensure the settings are appropriate and flow is max...imized.
• Check the oxygen source: there is sufficient oxygen available and flowing through the device. If FiO2 > 50% of oxygen is needed, the device must have a blender.
• Check there is no obstruction with secretions: patients with COVID-19 may have very thick secretions which may block small and large airways and cause sudden respiratory deterioration.
more
For patients on NIPPV or HFNO with persistent hypoxaemia or respiratory distress:
• Check the equipment: inspect the exterior of the machine, the tubing (circuit), the mask for any sign of mechanical damage, confirm it fits securely without leak (if CPAP/BiPAP) and the filters are in place. Ensur...e the settings are appropriate and flow is maximized.
• Check the oxygen source: there is sufficient oxygen available and flowing through the device. If FiO2 > 50% of oxygen is needed, the ventilator must have a blender.
• Check there is no obstruction with secretions: patients with COVID-19 may have very thick secretions which may block small and large airways and cause sudden respiratory deterioration.
more
The Global Programme to Eliminate Lymphatic Filariasis (LF) is using mass drug administration (MDA) of antifilarial medications to treat filarial infections, prevent disease and interrupt transmission. Almost 500 million people receive these medications each year. Clinical trials have recently shown... that a single dose of a triple-drug combination comprised of ivermectin, diethylcarbamazine and albendazole (IDA) is dramatically superior to widely used two-drug combinations for clearing larval filarial parasites from the blood of infected persons. A large mul-
ticenter community study showed that IDA was well-tolerated when it was provided as MDA. IDA was rapidly advanced from clinical trial to policy and implementation; it has the potential to accelerate LF elimination in many endemic countries.
more
Cardiovascular diseases (CVD) represent the highest burden of disease globally. Medicines are a critical intervention used to prevent and treat CVD. This review describes access to medication for CVD from a health system perspective and strategies that have been used to promote access, including pro...viding medicines at lower cost, improving medication supply, ensuring medicine quality, promoting appropriate use, and managing intellectual property issues. Using key evidence in published and gray literature and systematic reviews, we summarize advances in access to cardiovascular medicines using the 5 health system dimensions of access: availability, affordability, accessibility, acceptability, and quality of medicines. There are multiple barriers to access of CVD medicines, particularly in low- and middle-income countries. Low availability of CVD medicines has been reported in public and private healthcare facilities. When patients lack insurance and pay out of pocket to purchase medicines, medicines can be unaffordable. Accessibility and acceptability are low for medicines used in secondary prevention; increasing use is positively related to country income. Fixed-dose combinations have shown a positive effect on adherence and intermediate outcome measures such as blood pressure and cholesterol. We have a new opportunity to improve access to CVD medicines by using strategies such as efficient procurement of low-cost, quality-assured generic medicines, development of fixed-dose combination medicines, and promotion of adherence through insurance schemes that waive copayment for long-term medications. Monitoring progress at all levels, institutional, regional, national, and international, is vital to identifying gaps in access and implementing adequate policies.
more
Since the discovery of insulin nearly 100 years ago, advances in diabetes treatments and therapies have transformed the lives of people
with diabetes (PwD), notably reducing the daily burden of its management.
Newer technologies, including those driven by artificial intelligence, have the potentia...l to further improve the quality of life of PwD and help
identify and diagnose people at risk of developing Type 2 diabetes and diabetes-related complications early. However, medical and technological advances alone are not enough to fix the diabetes challenge. It is also critical to acknowledge the complexity and the seriousness of diabetes, its impact on the quality of life and well-being of over 32 million PwD in the EU and the financial burden it represents for health systems and society at large.
more